Related Experiment Video

Updated: May 17, 2026

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough

Alexandre Hinzpeter1, Abdel Aissat, Alix de Becdelièvre

  • 1INSERM U955, Créteil 94000, France.

Human Mutation
|October 16, 2012
PubMed

Insights

Readthrough therapy for genetic diseases is promising but variable. This study found that alternative splicing and transcript levels impact treatment efficacy, requiring careful assessment for optimal outcomes.

Area of Science:

  • Genetics
  • Molecular Biology
  • Pharmacology

Background:

  • Premature termination codons (PTCs) cause genetic diseases by creating truncated proteins.
  • Readthrough agents offer a potential therapeutic strategy by enabling ribosomes to bypass PTCs.
  • Treatment efficacy is influenced by factors like stop codon context and nonsense-mediated decay (NMD).

Purpose of the Study:

  • To investigate the impact of different PTCs in CFTR exon 15 on splicing and transcript levels.
  • To evaluate the effects of pharmacological treatments on readthrough efficiency and exon inclusion.
  • To determine factors influencing the efficacy of readthrough therapy for genetic disorders.

Main Methods:

  • In vitro minigene assay to screen all six PTCs in CFTR exon 15.
  • Assessment of alternative splicing patterns and transcript abundance for each PTC.
  • Pharmacological treatment to modulate exon inclusion and readthrough efficacy.

Main Results:

  • Five of six PTCs in CFTR exon 15 exhibited alternative splicing.
  • Mutations c.2537G>A and c.2551C>T resulted in the highest proportion of transcripts lacking exon 15 due to altered splicing regulatory elements.
  • Pharmacological interventions showed variable effects on exon inclusion, with both positive and negative impacts observed for the same mutation.

Conclusions:

  • Alternative splicing and transcript levels are critical determinants of readthrough therapy efficacy.
  • Comprehensive assessment of splicing profiles and total transcript amounts is necessary to predict and enhance treatment outcomes.
  • Understanding PTC context and its effect on splicing is crucial for developing effective genetic disease therapies.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...